Drugs / TERN-201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04897594 | May 2021 → Sep 2022 | metabolic dysfunction-associated steatohepatitis | Terns, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TERN-201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04897594 ↗ |
| Route | Oral | “Orally administered” NCT04897594 ↗ |